抗体-寡核酸合物的制药开发取得了进展
Meng Li1, Hongxin An1, Jialing Zhang1
1State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, China.
抗体-寡核酸合物 (AOC) 通过结合抗体和寡核酸提供向治疗. 本次审查涵盖了它们的开发,制造和质量控制,以确保安全有效的疾病治疗.
科学领域:
- 生物技术是生物技术.
- 治疗开发的治疗方法
- 分子医学是分子医学.
背景情况:
- 抗体-寡核酸合物 (AOC) 是新兴的治疗方法.
- 它们将抗体向与寡核酸基因调节结合在一起.
- 澳洲原产地有潜力治疗各种疾病.
研究的目的:
- 审查AOCs的历史和临床发展.
- 专注于作用机制,分子设计和制造.
- 突出AOC发展的挑战和未来前景.
主要方法:
- 对AOC史和临床试验的文献综述.
- 分子设计的分析,包括链接技术.
- 检查制造工艺和质量控制策略.
主要成果:
- 尽管发展处于早期阶段,但AOC表现出稳定的进展.
- 结构复杂性给制造和质量控制带来了挑战.
- 确保有效性和尽量减少毒性是关键考虑因素.
结论:
- AOC的设计,制造和质量控制对于安全性和有效性至关重要.
- 克服当前的挑战对于推进AOC疗法至关重要.
- 持续的研究有望显著的治疗潜力.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
09:06Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
Published on: December 23, 2016
相关概念视频
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Phase II Conjugation Reactions: Overview
